SCHEMBL4456743

SCHEMBL4456743

O=C(N(c1ccc(F)cc1)c1ccc(-c2c[nH]c(COc3ccccc3)n2)cc1)C(F)(F)F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
MAPT P10636 1/20 0.40
ADORA3 P0DMS8 1/20 0.37
ADORA2A P29274 1/20 0.37
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
SCN9A Q15858 4/20 0.35
MMP1 P03956 1/20 0.35
MMP2 P08253 1/20 0.35
MMP9 P14780 1/20 0.35
MMP13 P45452 1/20 0.35
MCL1 Q07820 3/20 0.34
GRM5 P41594 1/20 0.34
BCL2L1 Q07817 1/20 0.34
LMNA P02545 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34
FFAR1 O14842 1/20 0.34
FFAR4 Q5NUL3 1/20 0.34
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL4460353 0.80 MCL1 (0.47) MCL1FFAR1FFAR4
SCHEMBL4460188 0.79 NPC1 (0.45) MEN1KMT2AMAPTNPC1RAB9A
Trifluoroacetic Acid SCHEMBL4456741 0.79 MEN1 (0.57) MEN1KMT2AMAPTNPC1RAB9A
Trifluoroacetic Acid SCHEMBL4470387 0.78 PPARG (0.41) MEN1KMT2AMAPTRAB9AMCL1
SCHEMBL4461353 0.77 MEN1 (0.62) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL4684267 0.77 MEN1 (0.62) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL4681552 0.76 NR4A2 (0.49) NPC1RAB9AMCL1
SCHEMBL8216243 0.76 MCL1 (0.38) SCN9AMCL1
Trifluoroacetic Acid SCHEMBL4458367 0.76 MCL1 (0.48) KMT2ANPC1RAB9AMCL1LMNA
Formaldehyde SCHEMBL4470383 0.75 FFAR4 (0.39) MCL1LMNAFFAR1FFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7534805-B2 Imidazole derivatives, their preparation and their use as medicaments SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2009-05-19 US claimed
US-20070066542-A1 Novel imidazole derivatives, their preparation and their use as medicaments SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATION SCIENTIFIQUES (S.C.R.A.S.) (FR) 2007-03-22 US claimed
US-7534805-B2 Imidazole derivatives, their preparation and their use as medicaments SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2009-05-19 US disclosed
US-20070066542-A1 Novel imidazole derivatives, their preparation and their use as medicaments SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATION SCIENTIFIQUES (S.C.R.A.S.) (FR) 2007-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070066542-A1 Novel imidazole derivatives, their preparation and their use as medicaments MIF, MCL1, PPIP5K2 MEN1 280/4885KMT2A 1755/4885MAPT 2398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.